# Effect of Spironolactone in the Prevention of Anthracycline-induced Cardiotoxicity (SPIROTOX)

> **NCT06005259** · PHASE4 · UNKNOWN · sponsor: **University of Sao Paulo** · enrollment: 264 (estimated)

## Conditions studied

- Cardiotoxicity
- Neoplasms
- Chemotherapy Effect
- Heart Failure

## Interventions

- **DRUG:** Spironolactone
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06005259
- **Lead sponsor:** University of Sao Paulo
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-10-01
- **Primary completion:** 2025-10-01
- **Final completion:** 2025-12-01
- **Target enrollment:** 264 (ESTIMATED)
- **Last updated:** 2023-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06005259

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06005259, "Effect of Spironolactone in the Prevention of Anthracycline-induced Cardiotoxicity (SPIROTOX)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06005259. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*